Patents by Inventor Eric Mull

Eric Mull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis C virus inhibitors
    Patent number: 8957203
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: February 17, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P. V. K. Suresh Babu, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20140294898
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 2, 2014
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Compounds for the treatment of hepatitis C
    Patent number: 8765944
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: July 1, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric Mull, Qian Zhao, Tao Wang, Zhongxing Zhang, Paul Michael Scola
  • Compounds for the treatment of hepatitis C
    Patent number: 8741884
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: June 3, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Annapurna Pendri, Guo Li, Samuel Gerritz, Weixu Zhai, Paul Michael Scola, Li-Qiang Sun, Eric Mull
  • Compounds for the treatment of hepatitis C
    Patent number: 8586584
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 19, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
  • Compounds for the treatment of hepatitis C
    Patent number: 8445490
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: May 21, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
  • Hepatitis C Virus Inhibitors
    Publication number: 20130115190
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: April 30, 2012
    Publication date: May 9, 2013
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P. V. K. Suresh Babu, Paul Michael Scola
  • Compounds for the Treatment of Hepatitis C
    Publication number: 20120213729
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: August 16, 2011
    Publication date: August 23, 2012
    Inventors: Li-Qiang Sun, Eric Mull, Qian Zhao, Tao Wang, Zhongxing Zhang, Paul Michael Scola
  • Compounds for the Treatment of Hepatitis C
    Publication number: 20120093767
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: April 14, 2011
    Publication date: April 19, 2012
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, Annapurna Pendri, Guo Li, Samuel Gerritz, Weixu Zhai, Paul Michael Scola, Li-Qiang Sun, Eric Mull
  • Compounds for the Treatment of Hepatitis C
    Publication number: 20120093766
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 19, 2012
    Inventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
  • Compounds for the Treatment of Hepatitis C
    Publication number: 20110086858
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: October 14, 2010
    Publication date: April 14, 2011
    Inventors: Tao Wang, Annapurna Pendri, Zhongxing Zhang, Weixu Zhai, Guo Li, Samuel Gerritz, Paul Michael Scola, Li-Qiang Sun, Qian Zhao, Eric Mull
  • Pyrimidine Derivatives
    Publication number: 20090258888
    Abstract: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.
    Type: Application
    Filed: April 7, 2006
    Publication date: October 15, 2009
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Dhanapalan Nagarathnam, Yuanwei Chen, Wenlang Fu, Donald Bierer, Ming Wang, Michael Brands, Yamin Wang, Brian R. Bear, Aaron Schmitt, Eric Mull, David Miller, Jin Zhao
  • Indane amides
    Publication number: 20090247590
    Abstract: The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.
    Type: Application
    Filed: October 14, 2005
    Publication date: October 1, 2009
    Applicant: Bayer Pharmaceuticlas Corporation
    Inventors: Yamin Wang, Tindy Li, Eric Mull
  • 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders
    Publication number: 20060189609
    Abstract: The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 24, 2006
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, William Bullock, David Gunn, Qingjie Liu, Sidney Liang, Donglei Liu, Steven Magnuson, Tindy Li, Eric Mull, Jill Wood, Ning Qi
  • Hydroxamic acids useful in the treatment of hyper-proliferative disorders
    Publication number: 20060063760
    Abstract: This invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.
    Type: Application
    Filed: April 16, 2004
    Publication date: March 23, 2006
    Applicant: BAYER PHARMACEUTICALS CORPORATION
    Inventors: Yamin Wang, Maio Dai, Holia Hatoum-Mokdad, Zhengqiu Hong, Harold Kluender, Gaetan Ladouceur, Tindy Li, Derek Lowe, Eric Mull, Tatiana Shelekhin, Roger Smith, Wai Wong
  • Compounds and compositions for the treatment of diabetes and diabetes-related disorders
    Publication number: 20060009483
    Abstract: The present invention relates to novel compounds which are useful in the treatment of diabetes and diabetes-related disorders. The invention also relates to pharmaceutical compositions comprising said compounds, intermediates useful in the preparation of said compounds, and methods of preparation.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 12, 2006
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Yamin Wang, Eric Mull